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Abstract
Circulating tumor cells (CTCs) isolated from blood can be probed for the expression of treat-
ment targets. Immunofluorescence is often used for both the enumeration of CTC and the
determination of protein expression levels related to treatment targets. Accurate and repro-
ducible assessment of such treatment target expression levels is essential for their use in
the clinic. To enable this, an open source image analysis program named ACCEPT was
developed in the EU-FP7 CTCTrap and CANCER-ID programs. Here its application is
shown on a retrospective cohort of 132 metastatic breast cancer patients from which blood
samples were processed by CellSearch® and stained for HER-2 expression as additional
marker. Images were digitally stored and reviewers identified a total of 4084 CTCs. CTC’s
HER-2 expression was determined in the thumbnail images by ACCEPT. 150 of these
images were selected and sent to six independent investigators to score the HER-2 expres-
sion with and without ACCEPT. Concordance rate of the operators’ scoring results for HER-
2 on CTCs was 30% and could be increased using the ACCEPT tool to 51%. Automated
assessment of HER-2 expression by ACCEPT on 4084 CTCs of 132 patients showed 8
(6.1%) patients with all CTCs expressing HER-2, 14 (10.6%) patients with no CTC express-
ing HER-2 and 110 (83.3%) patients with CTCs showing a varying HER-2 expression level.
In total 1576 CTCs were determined HER-2 positive. We conclude that the use of image
analysis enables a more reproducible quantification of treatment targets on CTCs and leads
the way to fully automated and reproducible approaches.
Introduction
Peripheral blood tumor load represented by CTC is associated with poor outcome in cancer
patients [1–5]. The availability of CTCs allows for the assessment of treatment targets and
opens the avenue to provide CTC-based therapy to the patient. The ability to detect treatment
PLOS ONE | https://doi.org/10.1371/journal.pone.0186562 October 30, 2017 1 / 12
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPENACCESS
Citation: Zeune L, van Dalum G, Decraene C,
Proudhon C, Fehm T, Neubauer H, et al. (2017)
Quantifying HER-2 expression on circulating tumor
cells by ACCEPT. PLoS ONE 12(10): e0186562.
https://doi.org/10.1371/journal.pone.0186562
Editor: Jeffrey Chalmers, The Ohio State University,
UNITED STATES
Received: June 14, 2017
Accepted: October 3, 2017
Published: October 30, 2017
Copyright: © 2017 Zeune et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: The software code is
open-source and can be downloaded from https://
github.com/LeonieZ/ACCEPT. Analyzed samples
are from the Detect III and Beverly02 studies.
Original images cannot be provided but all
extracted measurements necessary to reproduce
the results are found in supplemental table S1
Table. The images that we analyzed in our paper
were patient samples analyzed with and exported
from the Cellsearch® system. In articles in PlosOne
(and other journals) using data generated with the
CellSearch system it is the standard to not share
data that has been processed. This is due to the
targets on CTC has been demonstrated in a variety of studies [6–12]. Before this information
can be used in the clinic it is imperative that such a target can be reproducibly and consistently
quantified on the CTC at different clinical sites. Although the majority of multicenter studies
have been performed with the FDA cleared CellSearch1 system, in recent years many systems
have been introduced to detect and isolate CTCs [13,14,15]. The lack of a unified approach to
designate a cell as a CTC, and to determine whether or not a CTC expresses a treatment target,
leads to large differences in reported CTC numbers and positivity rates for potential therapeu-
tic targets such as HER-2 between various studies urging the need for standardization. To
address this issue a CTC image analysis algorithm for identification and characterization of
CTC is being developed in the EU funded CANCER-ID & CTCTrap programs. Here we intro-
duce the first version of the Open Source program named ACCEPT (Automated CTC Classifi-
cation Enumeration and PhenoTyping) that allows for the quantification of treatment targets
on annotated CTCs. ACCEPT is a toolbox in which a novel efficient parameter-free multi-
scale segmentation method is used to identify objects in images captured by several CTC plat-
forms [16]. Here we investigate a retrospective set of images generated from CTCs detected in
metastatic breast cancer patients’ blood by the CellSearch1 system in which the expression of
HER-2 is assessed. Images generated by the CellSearch1 system were used as this system is
standardized and in use in multiple centers. But any annotated set of tiff images can be ana-
lyzed using the toolbox, allowing for the quantification of markers independent of the CTC
enrichment platform that is used. The toolbox is available for use at https://github.com/
LeonieZ/ACCEPT.
Materials and methods
CTC enumeration and HER-2 assessment
The CellSearch1 system (Menarini Silicon Biosystems Inc, Huntingdon Valley, PA, USA) was
used to enumerate CTCs and to assess their relative HER-2 expression. The cells enriched
from 7.5 ml of blood by EpCAM-expression were labeled with phycoerythrin (PE) conjugated
antibodies directed against epithelial cell specific cytokeratins (CKs), with an allophycocyanin
conjugated (APC) antibody directed against leukocyte specific CD45, and with a Fluorescein
(FITC) conjugated antibody (HER81) directed against HER-2. Additionally, cells were stained
with the nuclear dye 4,6-diamidino-2-phenylindole (DAPI) to identify the nucleus. The Cell-
Tracks Analyzer II1 (Menarini Silicon Biosystems Inc) was used to acquire digital images of
the four different fluorescent dyes using a 12-bit camera that are transformed and store as
8-bit images during archiving. Trained operators reviewed thumbnail images generated by the
CellTracks Analyzer II1 to count and determine the HER-2 expression of the CTCs according
to the manufacturer’s instructions.
Cell lines
Breast carcinoma cell lines SKBR-3, MDA-MB 453 and MDA-MB 231 were obtained from
ATCC (Manassa, VA, USA) and cultured in DMEM (Gibco, Life Technologies, Waltham,
MA, USA) containing 2 mM L-glutamine (G7513, Sigma-Aldrich), 100 U/mL penicillin and
100 μg/mL streptomycin (P4333, Sigma-Aldrich) and 10% FBS (F4135, Sigma-Aldrich) at
37˚C in a humidified 5% CO2 incubator. Cells were trypsinized at about 80% confluence with
0.05% Trypsin-EDTA (1X) with Phenol Red (Gibco, Life Technologies). HER-2 quantification
was performed with flow cytometry using the QuantiBRITE1 PE quantification kit (BD bio-
sciences, San Jose, California) using a previously published protocol [17]. Peripheral blood of
healthy donors was spiked with either 1500 SKBR-3, 500 MDA-MB 453 or 500 MDA-MB 231
cells and processed with the CellSearch1 system.
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fact that during data export an metadata xml file is
created which contains patient information and
machine identification. This metadata can of course
not be shared but is required by our toolbox to
process the images. Therefore we cannot share the
raw datasets that contain patient specific
information but prepared an excel table where all
measurements that we extracted are listed. This
data can be used to reproduce all graphs in the
publication. The important contribution in our
paper is the open-source toolbox that can be used
by interested researchers on any CellSearch
dataset for reproduction.
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Patients
In this study CTC images generated by the CellSearch1 system (Menarini Silicon Biosystems
Inc) from 132 patients with metastatic breast cancer were used. 80 patients (36 recruited in the
Department of Gynecology and Obstetrics—Ludwig-Maximilians-University, Munich and 44
in the Department of Gynecology and Obstetrics—Heinrich-Heine-University, Duesseldorf)
were enrolled in the Detect III study (NCT01619111). The other 52 patients were enrolled in
the BEVERLY02 study from Paris (NCT00717405). All patient identifying information is
maintained at the clinical sites and no access to this information was available for our analysis.
Approval for HER-2 CTC analysis was obtained by the independent ethics committee for
both, the Detect III study (Ethical Committee of the Heinrich-Heine University Duesseldorf)
and the BEVERLY02 study (Comite´ de Protection des Personnes Sud Me´diterrane´e I), and all
patients provided written informed consent.
Image analysis
The images were reanalyzed using the newly developed image analysis toolbox for CTC analy-
sis ACCEPT (Automated CTC Classification Enumeration and PhenoTyping). The software
is written in Matlab 2016a (Mathworks, Natick, MA). Next to the source code a compiled
standalone executable version, that includes the MATLAB Runtime and allows royalty-free
deployment for users who do not need MATLAB, is also available. In ACCEPT objects of
interest are segmented based on shape contours and intensity. The underlying algorithm to
automatically detect multiple objects with different scales is described in detail elsewhere
[16,18,19]. The main tool of the ACCEPT toolbox is a fully automated detection and classifica-
tion approach for blood samples but in this paper we introduce a second tool, called the
Marker Characterization tool, that reproducibly evaluates the marker expression of prescored
cells and can aid users to manually score or quantify cells and their fluorescent signals.
The thumbnail images of all 4084 manually scored CTCs out of 132 patients were loaded
into the ACCEPT algorithm. The images that are stored as 8-bit images by the CellSearch1
system with an image brightness automatically adjusted relative to the brightest pixel in the
channel, are rescaled before processing to their true intensity values by extracting the original
minimum and maximum value in each channel from the accompanying tiff header. After-
wards the outline of all events present in these images was automatically detected in each chan-
nel. Based on these contours, we extracted seven different measurements per object and per
fluorescent channel, i.e. eccentricity (circularity measure), perimeter, mean intensity, maxi-
mum intensity, size, standard deviation of the intensity, mass (sum of all intensity values) and
perimeter2area (circularity measure). Moreover, we extracted the relative overlay of the signals
in the DAPI and CD45 channels and in the DAPI and CK channels. The thumbnail images
together with the extracted contour and measurements are presented to the operator to deter-
mine the HER-2 expression.
Results
Visualization of CTC by ACCEPT
In Fig 1 the visualization of CTCs in the ACCEPT toolbox is shown. Some sample information
is presented on the top left with a scaled overview image of the sample next to it. The main
components of the visualization window are the thumbnail gallery on the left and three scatter
plots on the right. The thumbnail gallery presents an overlay image of the first three fluores-
cent markers (CD45, DAPI, CK) and next to it a thumbnail image of every single fluorescent
channel. While the overlay image is scaled, the single channels present the full, unscaled
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intensity range to prevent misinterpretation of the signal. For the three marked cells a scaled
version is depicted below the visualization window. While the scaled visualization gives the
impression that all three cells have a similar expression, a precise segmentation of the signal as
done in ACCEPT (indicated by the red contour) shows that their mean intensity does differ.
The standard deviation of the background signal is in this case 6.6 on average. A two-sided t-
test shows that the intensity difference between thumbnail one and three as well as between
two and three is statistically meaningful. In the unscaled image, interpretation faults like this
are prevented. Very dim signals (like the HER-2 expression of the three selected cells) are diffi-
cult to see, but the red contour shows that a signal is presented and the dots in the scatter plots
on the right visualize the extracted measurements such as the mean intensity. In Fig 1 we plot-
ted the CK versus DAPI mean intensity, CK versus CD45 mean intensity and CK versus HER-
Fig 1. Sample Visualizer of ACCEPT. In the scatter plots 3 of the 158 objects are depicted blue and the corresponding thumbnail images are
highlighted. In this example ‘Marker1’ represents signals for HER-2. The corresponding HER-2 images are shown below the Sample Visualizer,
in the right image the red line indicates the boundary detected by ACCEPT of the identified CTC and the number indicates the median value of
the HER-2 staining within this boundary. Size bar in overlay: 6.4μm.
https://doi.org/10.1371/journal.pone.0186562.g001
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2 mean intensity. Moreover, right clicking on an image in the thumbnail gallery opens a scaled
visualization.
HER-2 expression on breast cancer cell lines
To define a threshold for positive HER-2 expression, we evaluated the HER-2 mean intensity
of the three breast cancer cell lines SKBR-3 (3+), MDA-MB 453 (2+) and MDA-MB 231 (0 or
1+). Fig 2A depicts the scatter plot of the CK mean intensities versus the HER-2 mean intensi-
ties for each cell line. Based on the HER-2 expression shown in panel A we defined 2 thresh-
olds to distinguish between HER-2 negativity (0 or 1+), dim HER-2 expression (2+) and bright
HER-2 (3+) expression: a dim HER-2 expression has a mean intensity between 0 and 100 and
a bright HER-2 expression has a mean intensity above 100. With these thresholds 87.15% of
the cells were correctly classified (Fig 2B). Note that a cutoff of 0 is sufficient to distinguish
between HER-2 negative and dim HER-2 expression since a separating gap between these two
classes is automatically constructed by our segmentation method. Yet we see that overall the
HER-2 expression is very low; the maximal possible intensity is 4095 while the highest mea-
sured mean intensity in the 3+ positive cell line is around 1000. To ensure that the measured
signal intensity correlates to the number of antigens we compared the median intensity value
and coefficient of variation (CV) for each of the three cell lines to the number of HER-2 anti-
gens determined by measuring their mean expression levels by flow cytometer using the BD
Quantibrite™ Beads PE Fluorescence Quantitation Kit (BD Biosciences, San Jose, CA, USA).
The average expression of HER-2 on the SKBR-3 cells was 957.731 (CV 78.4%) HER-2 anti-
gens, MDA-MB 453 had 335.075 (CV 62.9%) HER-2 antigens and MDA-MB 231 expressed
19.958 (CV 108.1%) HER-2 antigens. This is in line with literature [20]. These values result in
a linear correlation (see S1 Fig) and show that the measured mean intensity is a valid measure
for the HER-2 expression. This was also previously shown in [21]. The authors showed that
the HER-2 signal of the cells found using this assay relates to the gene copy number in their
cohort.
Fig 2. Cytokeratin and HER-2 mean intensities of cells in breast cancer cell lines MDA-MB 231, MDA-MB 453 and
SKBR-3. Panel A, 373 MDA-MB 231 cells (magenta), 496 MDA-MB 453 cells (cyan), 361 SKBR-3 cells (orange). Average
number of HER-2 antigens included for each cell line. Panel B classification of the MDA-MB 231, MDA-MB 453 and SKBR-
3 into 428 negative HER-2 (green), 462 dim HER-2 (blue) and 340 bright HER-2 (red) expressing cells identified by cluster
analysis.
https://doi.org/10.1371/journal.pone.0186562.g002
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HER-2 expression of CTC in metastatic breast cancer patients
We evaluated the HER-2 expression of 4084 CTCs from 132 metastatic breast cancer patients
and applied the same thresholds as with the cell lines in Fig 2. Fig 3 shows a scatter plot with
the CK mean intensity (x-axis) versus the HER-2 mean intensity (y-axis). Again, all CTCs not
expressing HER-2 are depicted in green (61.4%), CTCs with a dim HER-2 expression between
1 and 99 are labeled blue (36.2%) and those with a bright HER-2 mean expression larger or
equal to 100 are colored in red (2.4% of all CTCs).
Heterogeneity of HER-2 expression per patient
For each of the 132 patients we evaluated the heterogeneity of HER-2 expression in CTCs. The
results are shown in Fig 4 and are sorted from left to right according to decreasing percentages
of CTCs that are HER-2 dim or bright (HER-2 > 0). Again, HER-2 negative CTCs are colored
in green, dim HER-2 in blue and bright HER-2 in red. In 8 (6.1%) patients all CTCs expressed
HER-2, in 14 (10.6%) patients none of the CTCs expressed HER-2 and in 110 (83.3%) patients
various HER-2 expression levels on CTCs were observed. Thus, for most patients not all CTCs
express or lack HER-2, most patients rather present CTCs with varying levels of HER-2 signal.
HER-2 expression of CTC assessed by operators and ACCEPT
To assess whether the defined thresholds correlate with manual scoring, we compared for each
of the 132 samples the number of automatically scored HER-2 positive CTCs (HER-2 mean
intensity > 0) with the number of CTCs that were manually scored as HER-2 positive (2+ or
Fig 3. Expression of Cytokeratin and HER-2 on 4084 CTCs in 132 breast cancer patients. HER-2 negative
CTCs are colored in green, dim HER-2 (0 <HER-2 < 100) in blue and bright HER-2 (100) in red.
https://doi.org/10.1371/journal.pone.0186562.g003
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3+) by the three clinical sites. The results are shown in Fig 5. We observe a good agreement
between the scores of sites 2 and 3, yet on average they manually scored more cells as HER-2
positive than our automated procedure. Nevertheless, there is a reasonably high Pearson
correlation between the manual and automatic scores for site 2 (coefficient r = 0.82) and site 3
(coefficient r = 0.98). Operators of site 1 were much stricter with their definition of HER-2
positivity and scored fewer cells as positive compared to the automated approach. This results
in a much lower correlation coefficient (r = 0.51). To compare the number of manually and
automatically scored cells to a “ground truth” solution, further experiments are necessary to
obtain images of cells where the HER-2 expression is known. Yet, in this work, we concentrate
on retrospectively studying samples that were investigated before. The main goal of the Marker
Characterization tool of the ACCEPT toolbox is to reproducibly quantify manually scored
cells and aid users to unify their scoring results. Yet, any approach that is still to some part
manual will not give fully reproducible and unified results. This highly motivates the use of a
fully automated approach, as it will be possible in another tool of the ACCEPT software, espe-
cially in multi-center studies to unify the scoring results.
Influence of quantitative display of HER-2 expression
In Fig 1 we have shown the difference between the traditionally scored visualization of fluores-
cent intensity (three examples at the bottom) and the visualization we used in the ACCEPT
tool. Since it is difficult to evaluate the intensity of a fluorescent signal based on a scaled image,
this way of visualizing data could be a major cause for the high inter-user variability observed
in manual scores. Therefore, we developed a tool to allow the operators to rate the HER-2
Fig 4. HER-2 expression in CTCs in each of the 132 patients. Patients are sorted according to the percentage of HER-
2+ CTCs using a threshold of (>0). HER-2 negative CTCs are colored in green, dim HER-2 in blue (0 < HER-2 < 100) and
bright HER-2 (100) CTCs red.
https://doi.org/10.1371/journal.pone.0186562.g004
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expression with and without the quantitative display of HER-2 expression in the form of a
scatterplot.
To test if the concordance between different operators can be increased when our tool is
used for scoring, a total of 150 randomly chosen images of CTCs were sent to six different
investigators for scoring HER-2 positivity. The results are shown in Fig 6. For scaled visualiza-
tion images in 30 percent of the cases all investigators agreed with a major part of agreement
on positivity (red box) although a large part of the cells had nearly no HER-2 expression by
quantitative assessment of HER-2 mean intensities. With the quantitative display in ACCEPT
this percentage of full agreement can be increased to over 50 percent (right graph). Here the
investigators agreed mostly on HER-2 negativity (blue box). Thus, the scaled visualization has
a high sensitivity but also a lot disagreement while the quantitative display leads to more true
negatives and therefore a higher specificity and less disagreement. To investigate which cells
have the highest probability to result in disagreement of reviewers, we compared the Cytokera-
tin and HER-2 mean intensity of each of the 150 cells to the number of reviewers that agree on
their HER-2 status. The results for both, the scaled and the ACCEPT visualization, are shown
in the supplemental figure S2 Fig. We see that the quantitative display significantly decreases
the spread of user disagreement. Yet, the Marker Characterization tool can still only help users
to make their decision therefore there are still 49% where at least one reviewer has a different
Fig 5. Number of manually scored HER-2+ cells versus number of automatically scored HER-2+ cells using a
threshold of >0. Samples of 132 patients were investigated.
https://doi.org/10.1371/journal.pone.0186562.g005
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opinion than the other ones. This illustrates the need for either automated classification of
CTCs as HER-2 positive CTCs or classification of HER-2 positive CTCs by using the ACCEPT
quantitative displays.
Discussion
Since treatment options for cancer patients are increasing rapidly and concurrently there is a
growing demand for biomarkers that can predict the most effective therapy. Availability of
tumor material before the start of a new line of therapy is imperative to determine the presence
of treatment targets to eradicate the tumor. However, a tumor or its metastasis might not
always be accessible for biopsy. Therefore, isolation of tumor cells from blood represents a
unique opportunity to obtain tumor material providing its latest genotypic and phenotypic fin-
gerprint. After demonstration that tumor cells can be reproducibly isolated from blood and
that their presence is related to poor clinical outcome [22] many new technologies have been
introduced to detect and isolate CTCs [13,14,15,23]. The lack of an automated unified
approach to designate a cell as a CTC and determine what is and what is not expressed is how-
ever impeding progress of the field. To address this issue, an open source image analysis pro-
gram ACCEPT is being developed in a consorted European effort enabling comparisons
between platforms and providing accurate and reproducible information. Here we introduce
the first applications of ACCEPT and demonstrate the ability to extract relative expression of
antigens expressed by CTCs. In addition, we show that the use of scatterplots and expression
levels of the antigens next to the fluorescence images helps to reduce inter reader variability in
terms of scoring of HER-2 positivity. Increased concordance in the expression of targetable
biomarkers will optimize the performance and results of clinical multicenter studies such as
the DETECT trial [24].
Fig 6. Comparisons of HER-2 assessment by different sites using ACCEPT versus CellTracks Analyzer II® (Menarini Silicon
Biosystems Inc) visualization. Indicated are the percentages of scored CTCs where all, five, four or only three out of six investigators
agreed on the HER-2 status. In the case of 3 agree indifferent means that three investigators vote for HER-2 positive and the other three for
HER-2 negative.
https://doi.org/10.1371/journal.pone.0186562.g006
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Of particular interest in this study is the large heterogeneity observed in the HER-2 expres-
sion of CTCs in breast cancer patients. After evaluation of the HER-2 signal CTCs were
divided up into three groups: HER-2 negative, HER-2 low and HER-2 high. This division was
based on the HER-2 expression levels measured on MDA-MB 231, MDA-MB 453 and SKBR3
breast cancer cells. A more meaningful division may be to discriminate subgroups based on
the effect of a HER-2- targeted treatment on the CTCs directly. This could for example be
achieved by measuring HER-2 expression levels of CTCs before and after administration of a
HER-2 targeted therapy.
In earlier studies, we developed computer generated CTC definitions using overall survival
of the patients as the training parameter [21] and extract information from the identified CTC
[25,26]. In this study, we used advanced mathematical approaches to identify objects in the
images and to extract features from the identified objects [16]. More importantly, we make the
program available for all researchers with an interest in identifying and characterizing CTCs
or other objects and enable the comparison of fluorescence signals generated with different
imaging platforms. By using the tools provided in ACCEPT differences in the effectiveness of
different treatments targeting the HER-2 receptor can be assessed. The ACCEPT program and
manual can be downloaded from https://github.com/LeonieZ/ACCEPT.
Besides a more reliable and reproducible quantification of therapeutic marker expression,
our ultimate goal is to develop a common definition of a CTC. The large variety of cancer and
phenotypes makes it of course very challenging but using the input of a variety of users apply-
ing a variety of platforms together with the current breakthroughs in the field of machine
learning and imaging may help to understand differences and similarities in the CTCs between
different cancer and phenotypes in the future and enables us to find a common CTC definition
spanning at least a wide range of cancer and phenotypes.
Until then, a unified approach to the analysis of fluorescent images across CTC isolation
platforms and CTC phenotypes may increase robustness and lead to a higher reproducibility
of results as we have seen it in this study. In its current version, the software can load images
from several CTC isolation platforms. Moreover, it contains a general tiff-loader if no specific
sample information should be loaded. Loaders for different microscope system can be easily
integrated and are work in progress. Further features and tools will be available throughout the
IMI CANCER-ID program.
Supporting information
S1 Fig. Linear calibration of the number of HER-2 antigens and the measured HER-2 sig-
nal intensity. Values plotted for each of the investigated cell lines together with the corre-
sponding line equation and regression value.
(TIF)
S2 Fig. Comparisons of HER-2 assessment using ACCEPT versus CellTracks Analyzer II1
(Menarini Silicon Biosystems Inc) visualization in relation to measured mean intensities.
Expression of Cytokeratin and HER-2 on the 150 randomly chosen images of CTCs that were
sent to six different investigators for scoring HER-2 positivity. Marker colors indicate if all,
five, four or only three out of six investigators agreed on the HER-2 status. Panel A and C cor-
respond to the scaled visualization (C is a zoom-in of A) and panel B and D correspond to the
ACCEPT visualization (D is a zoom-in of B).
(TIF)
S1 Table. Data tables.
(XLSX)
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